Circulating Gene Transcript Analysis of Pancreatic NETs Abstract #1212

Introduction: PNETs are aggressive with poor survival. Therapeutic agents are available but efficacy determination is limited by imaging insensitivity and the lack of effective blood biomarkers.
Aim(s): Examine the utility of a blood transcript signature in comparison to CgA measurement.
Materials and methods: We assessed 2 separate prospectively collected datasets. Set 1: Graded PNETs (n=65; 25 resections). Set 2: unknown pancreas disease (n=61: pancreatitis n=4, cyst n=31, NET n=4, adenoCa n=22). Set 1 and 2: Gene expression (qPCR) and CgA (DAKO) were compared (χ2, non-parametric). Metrics were calculated for the entire cohort (n=126). Status was assessed clinically + RECIST. NETest index defined disease activity scaled 0-100%; minimal <20%, low 20-47%, high >47%.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Keywords: PNET, NETest, PCR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2958 The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction: Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
#344 Cell Cycle Phase Expression Profile Guided Selection of Proliferative Markers for Well-differentiated Small Intestinal Neuroendocrine Neoplasms
Introduction: Grading of neuroendocrine lesions is often determined by Ki-67 (immunostain), despite limited prognostic ability for this cell cycle marker in well-differentiated tumors (WDNETs) and carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
Authors: Lawrence B, Kidd M, Alaimo D, Svejda B, ...
#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)
Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Authors: Modlin I M, Kidd M, Drozdov I, Alaimo D, ...
Keywords: biomarker, CgA, NET, PCR
#913 A PCR-Based Multigene Transcript Analysis Blood Test Outperforms Chromogranin A in the Detection of Gastrointestinal and Pancreatic Neuroendocrine Tumors and is Unaffected by PPI Use or Hypertension
Introduction: A critical requirement in the management of gut NETs is a blood biomarker test that is sensitive, specific and reproducible.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Keywords: biomarker, CgA, NET, PCR